Ongoing work aims to integrate our knowledge of the biology and immunobiology of HNSCC to identify effective biomarkers that will enable more accurate and less toxic therapeutic options.[11] Overexpression of EGFR is associated with advanced disease stages, underpinning the role of EGFR in tumor metastasis and invasion in patients with laryngeal cancer.[12] Therefore, targeting EGFR is considered a reliable therapeutic strategy for patients with HNSCC. The gene discussed is EGFR; the disease is neoplasm.